Skip to main content
Caplight Logo









OxyNov Inc.

OxyNov Inc.

Private
CanadaHealthcare & Life Scienceshttps://www.oxynov.com/

Last Round

Grant

Feb 2, 2021

Total Funding Raised

$180,000

Company Overview

OxyNov Inc. is a medical device company that develops and commercializes automated oxygen therapy systems, including its flagship FreeO₂ device, to optimize respiratory care and improve patient outcomes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

automated oxygen therapyoxygen titrationmedical deviceclosed-loop controlSpO2 monitoringrespiratory caresmart ventilatorintensive care technologyoxygen saturationdigital healthhealth IoTclinical automationpatient monitoringrespiratory therapymedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OxyNov Inc. Comparables

Compare OxyNov Inc. with similar companies based on industry and business-model similarity.

OxyNov Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
O2matic ApS
89%
Masimo Corporation
78%
Vapotherm
76%

OxyNov Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 2, 2021
Series AOct 17, 2018
VC RoundMar 15, 2017

Key People

Founding team and executive leadership

Patrice Allibert

President and Chief Executive Officer

Executive Team

Marie-Josée Paré

CFO (part time), member of the Executive Commitee and the Strategic Commitee of the BoD

Executive Team

OxyNov Inc. Investors

Notable investors and investment history

OxyNov Inc. investors
InvestorRounds
Desjardins CapitalVC Round, Series A
Anges QuebecVC Round
Ville de QuébecGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 2, 2021

    $180K grant received from Ville de Québec

  • Oct 17, 2018

    Led by Vygon with participation from Desjardins Capital.

OxyNov Inc. Filings

Explore SEC and related filing metadata, where available.

OxyNov Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about OxyNov Inc.'s valuation, stock price, and market status.

Is OxyNov Inc. a public or private company?

OxyNov Inc. is a private company.

What is the current stock price of OxyNov Inc.?

OxyNov Inc. is a private company with no public stock price. Caplight tracks OxyNov Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is OxyNov Inc. worth (valuation)?

Valuation information for OxyNov Inc. is not publicly available.

Can I buy OxyNov Inc. stock?

OxyNov Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was OxyNov Inc.'s last funding round?

OxyNov Inc.'s most recent funding round was Grant on February 2, 2021.

Who are the main investors in OxyNov Inc.?

Key investors in OxyNov Inc. include Desjardins Capital, Anges Quebec, Ville de Québec.

Will OxyNov Inc. IPO soon?

No public IPO plans have been announced for OxyNov Inc..

How can I track OxyNov Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OxyNov Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCanada
Employee Range17
Year Founded2009
Last FundingFeb 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?